LA-CB1

• Description :

  LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC50 of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer[1].

• CAS Number :

  [3032908-44-1]

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Concentration :

  10mM

• Purity :

  98.20

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CC1=NC2=C(C=C(C=C2N1C(C)C)C3=CC=NC(NC4=CC(Cl)=C(C=C4)OCC5=C(C=CC=N5)C#N)=N3)F

• Molecular Formula :

  C28H23ClFN7O

• Molecular Weight :

  527.98

• References & Citations :

  [1]He J, et al. Targeted degradation of CDK4/6 by LA-CB1 inhibits EMT and suppresses tumor growth in orthotopic breast cancer. Sci Rep. 2025 Mar 4;15 (1) :7605.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK4; CDK6